The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoro ethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents.

The present teachings are directed at polymers, polymeric compositions, polymerizable compositions, and articles including a 1,1-disubstituted alkene monomers (e.g., methylene beta-diketone monomers) and one or more formulation materials. The monomer preferably is a high purity monomer. Preferably, the amount of ketals (e.g., in the polymerizable composition) is less than about 100 ppm and/or the amount of latent acid-forming impurities (e.g., in the polymerizable composition) is less than about 100 ppm (e.g., based on the total weight of the monomer). Preferably, the methylene beta-diketone monomer is a high purity monomer having a purity of about 95 weight percent or more. The monomer(s) may be employed in compositions and products, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

The present teachings are directed at polymers, polymeric compositions, polymerizable compositions, and articles including a 1,1-disubstituted alkene monomers (e.g., methylene beta-diketone monomers) and one or more formulation materials. The monomer preferably is a high purity monomer. Preferably, the amount of ketals (e.g., in the polymerizable composition) is less than about 100 ppm and/or the amount of latent acid-forming impurities (e.g., in the polymerizable composition) is less than about 100 ppm (e.g., based on the total weight of the monomer). Preferably, the methylene beta-diketone monomer is a high purity monomer having a purity of about 95 weight percent or more. The monomer(s) may be employed in compositions and products, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents.

A method of preparing 4-methyl-3-decen-5-one. The method includes the step of oxidizing 4-methyl-3-decen-5-ol in the presence of (i) oxygen and (ii) a metal catalyst, wherein the metal catalyst contains a catalytic metal deposited on nanoparticle support.

A method of preparing 4-methyl-3-decen-5-one. The method includes the step of oxidizing 4-methyl-3-decen-5-ol in the presence of (i) oxygen and (ii) a metal catalyst, wherein the metal catalyst contains a catalytic metal deposited on nanoparticle support.

The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R.sub.1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5 and X.sub.6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease. ##STR00001##

The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R.sub.1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5 and X.sub.6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease. ##STR00001##

A method of preparing 4-methyl-3-decen-5-one. The method includes the step of oxidizing 4-methyl-3-decen-5-ol in the presence of (i) oxygen and (ii) a metal catalyst, wherein the metal catalyst contains a catalytic metal deposited on nanoparticle support.

A method of preparing 4-methyl-3-decen-5-one. The method includes the step of oxidizing 4-methyl-3-decen-5-ol in the presence of (i) oxygen and (ii) a metal catalyst, wherein the metal catalyst contains a catalytic metal deposited on nanoparticle support.